Funa K, Gazdar A F, Minna J D, Linnoila R I
Lab Invest. 1986 Aug;55(2):186-93.
Cell lines established from small cell lung cancer (SCLC), a neuroendocrine tumor, have low or absent expression of class I major histocompatibility complex antigens. To determine whether this phenomenon occurs also in vivo, 244 routine paraffin-embedded tumors including 32 SCLC and 79 non-SCLC (NSCLC) lung cancers were studied for expression of beta 2-microglobulin (beta 2m) by an avidin-biotin coupled immunoperoxidase technique. The majority of SCLC tumors lacked beta 2m expression, while some had weak, focal expression. In contrast, most NSCLC expressed beta 2m, often strongly. The difference between SCLC and NSCLC was highly significant statistically, suggesting that beta 2m can be used as a clinical immunodiagnostic marker for distinguishing NSCLC from SCLC. In addition, certain other neuroendocrine tumors (neuroblastoma, bronchial and midgut carcinoid tumors) lacked beta 2m expression, whereas some (pheochromocytoma, medullary thyroid carcinoma, and peripheral neuroectodermal tumors) usually stained positively. Such non-neuroendocrine tumors as colon, breast, and prostate carcinomas showed moderate to high expression of beta 2m. Selective absence of beta 2m expression by certain neuroendocrine tumors appears to be a phenomenon of biological and diagnostic importance.
从小细胞肺癌（一种神经内分泌肿瘤）建立的细胞系，其I类主要组织相容性复合体抗原的表达很低或缺失。为了确定这种现象在体内是否也会发生，我们采用抗生物素蛋白-生物素偶联免疫过氧化物酶技术，对包括32例小细胞肺癌和79例非小细胞肺癌（NSCLC）在内的244例常规石蜡包埋肿瘤进行了β2微球蛋白（β2m）表达的研究。大多数小细胞肺癌肿瘤缺乏β2m表达，而有些则有微弱的局灶性表达。相比之下，大多数非小细胞肺癌表达β2m，且常常是强表达。小细胞肺癌和非小细胞肺癌之间的差异在统计学上具有高度显著性，这表明β2m可作为区分非小细胞肺癌和小细胞肺癌的临床免疫诊断标志物。此外，某些其他神经内分泌肿瘤（神经母细胞瘤、支气管和中肠类癌肿瘤）缺乏β2m表达，而有些（嗜铬细胞瘤、甲状腺髓样癌和外周神经外胚层肿瘤）通常呈阳性染色。诸如结肠癌、乳腺癌和前列腺癌等非神经内分泌肿瘤显示出β2m的中度至高表达。某些神经内分泌肿瘤选择性缺乏β2m表达似乎是一种具有生物学和诊断重要性的现象。
